NIMH Senior Staffer Charged With Accepting Improper Payments From Pfizer
This article was originally published in The Pink Sheet Daily
Executive Summary
Charges relate to undisclosed consulting gig, U.S. attorney says.
You may also be interested in...
NIH Disclosure Of Outside Activities Differs From Pfizer Report, House Cmte. Finds
House Commerce Committee identifies 100 instances where drug companies reported consulting arrangements and the National Institutes of Health did not disclose those arrangements. In an effort to place "NIH ethics issues in context," the committee is requesting FDA and 14 other agencies submit lists of outside compensation.
Celgene To Submit Revlimid Phase III Special Protocol Assessment For CLL To FDA Shortly
Firm notes strong uptake of the product in 2006, as well as more than $400 million in Thalomid sales for the year during earnings call.
AstraZeneca Continues Pipeline Expansion Via Two Licensing Deals Totaling $800 Million
Agreements expand the firm’s position in the COPD space, while also entering obesity, diabetes and metabolic syndrome space.